Prescient Therapeutics Limited

Prescient Therapeutics Limited, a clinical stage oncology company develops drugs for the treatment of haematological and solid cancers in Australia. Its lead drug candidate is PTX-100, a first in class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1.

Formerly known as Virax Holdings Limited, the company rebranded as Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.